TKNO Alpha Teknova Inc

$TKNO Revenue reached $12.2 million in Q2 2026, and management raised its full-year revenue guidance to $45–$47 million, up from its earlier forecast of $42–$44 million.**

$TKNO Follow-up: Alpha Teknova, a California maker of lab reagents for drug and diagnostic developers, priced 8M new shares at $5.00, about 32% below the $7.39 close at 16:00 ET Oct 20. The $40M gross is 2.4x the $16.6M of Sept 30 cash and short-term investments estimated in the Oct 20 preliminary prospectus, which left size blank; it adds ~15% to 53.7M shares. Other side: proceeds may repay debt, $13.2M at June 30. Next: close about Oct 22; underwriters have 30 days to buy 1.2M more shares; 90-day lock-up.

If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $TKNO $EVMN $ENVX ##

$TKNO: Alpha Teknova guides Q3 revenue above consensus and prices a $40 million common stock offering at $5 per share.

Alpha Teknova announced an underwritten public offering of its common stock, with TD Cowen and William Blair acting as joint book-running managers. The company may grant underwriters a 30-day option to purchase up to 15% additional shares. Teknova will sell all offered shares and use the proceeds for general corporate purposes, including potential repayment of outstanding debt. The life sciences reagent manufacturer also released preliminary, unaudited Q3 2026 results, projecting revenue of $12.5M–$12.7M, above the $11.7M analyst consensus and representing 19%–21% year-over-year growth. Gross margin is expected to reach 36%–38%, expanding 500–700 basis points, while adjusted EBITDA is projected at -$1.2M to -$1.0M, improving at least 25% year over year due to continued cost discipline. Cash and short-term investments totaled approximately $16.6M as of September 30, 2026. $TKNO

$TKNO Alpha Teknova, a California maker of lab reagents for drug and diagnostic developers, issued preliminary Q3 2026 numbers alongside an underwritten stock sale, size not yet set, run by TD Cowen and William Blair. Est. cash and short-term investments of $16.6M at Sept 30 (from $17.4M June 30) sit beside $13.2M of debt at June 30 and a ~$397M market value at $7.40 (16:00 ET Oct 20). Other side: Q3 revenue est. $12.5-12.7M, up 19-21% y/y, against a $45-47M 2026 revenue guide given Aug 5; proceeds may repay debt. Next: pricing, then a 90-day lock-up.